#USA #San Diego #QuidelOrtho #Transfusion Medicine #AABB 2025

QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

QuidelOrtho Corporation, a front-runner in in vitro diagnostics, recently made headlines at the Association for the Advancement of Blood Biotherapies (AABB) 2025 Annual Meeting. The event served as a platform for the company to reaffirm its dedication to advancing transfusion medicine, particularly highlighting the recent FDA approval of its Micro Typing Systems (MTS) DAT Card.

At this prestigious gathering, QuidelOrtho emphasized its state-of-the-art solutions in direct antiglobulin testing, integrating advanced technology into their suite of immunohematology products. The MTS DAT Card is a key addition to the company's gel-based system, serving to enhance laboratory performance and provide timely results required for critical transfusion decisions.

According to Michelle Mullens, Global Product Manager for Portfolio Solutions in Transfusion Medicine, the AABB Annual Meeting is an essential forum that unites the foremost experts in blood and biotherapies. She stated that QuidelOrtho’s participation reflects their commitment to innovation and efficiency, ultimately aimed at improving patient care worldwide.

Highlights from the Conference

Featured Educational Sessions

The AABB conference included a variety of educational presentations aimed at addressing the complexities and challenges in transfusion medicine. These sessions included:

• - The Challenging World of Rh(D) Antigen by Sue T. Johnson, MSTM, MLS(ASCP)SBBCM: An exploration of the intricacies of Rh(D) antigen identification and its importance in transfusion safety.
• - Identifying the Imposter - How ID-MTS Gel Test Typing Can Help Blood Banks with DARA Patients by Lehang Dingh, MLS(ASCP)SBBCM: A discussion on utilizing gel testing to differentiate between true antibodies and drug interference in patients treated with daratumumab.
• - Type Seek Solution to the Patient Puzzle by Shane Grimsley, DipRCPath, FBBTS: An insightful session on advanced immunohematology techniques to resolve complicated serological cases.

Poster Presentations

Researchers at the conference also presented posters covering metrics that underscore laboratory decision-making capabilities. Topics included reliability assessments of instruments used in immunohematology testing and the evaluation of a new gel card designed for the detection of IgG and C3. These findings not only highlight the ongoing research within the field but also serve to enhance laboratory practices and patient outcomes.

Product Demonstrations

QuidelOrtho showcased its innovative instruments designed to improve operational efficiency in blood testing labs, including:

• - ORTHO VISION™ Max Swift Analyzer: Engineered for high-throughput labs, this analyzer offers exceptional speed, reliability, and automation.
• - ORTHO VISION™ Swift Analyzer: A compact solution that ensures 98% operational uptime and produces high-quality results with the support of ID-MTS™ Gel Test technology.
• - ORTHO CONNECT™ Lab Management Software: This system streamlines lab workflows and helps address staffing challenges while ensuring compliance requirements are met.

Conclusion

QuidelOrtho’s presence at the AABB 2025 Annual Meeting underscored its leadership in transfusion medicine and its commitment to delivering innovative solutions that enhance laboratory efficiency and improve outcomes for patients reliant on timely transfusion interventions. The company’s ongoing investment in research and development signifies its dedication to shaping the future of diagnostics in the medical field beyond traditional practices.